Biotech Values

[DewDiligence]

ENTA reports HBV data_from_ 200mg_and_400mg_cohorts_of EDP-514 phase-1b:

https://www.enanta.com/investors/news-releases/press-release/2021/Enanta-Pharmaceuticals-Reports-Positive-Data-from-Part-2-of-its-Phase-1b-Study-of-EDP-514-in-Chronic-Hepatitis-B-Virus-Patients-on-Treatment-with-a-Nucleoside-Reverse-Transcriptase-Inhibitor/default.aspx

Enanta Pharmaceuticals…today announced positive data from the first two dose cohorts of Part 2 of its Phase 1b study of EDP-514 in chronic hepatitis B virus (HBV) patients already being treated with a nucleoside reverse transcriptase inhibitor (NUC). The data demonstrated that EDP-514, the Company’s novel class II oral HBV core inhibitor, was safe and well-tolerated, displayed pharmacokinetics (PK) supportive of once-daily dosing, and resulted in a mean reduction in HBV RNA of 1 log.

The 800mg cohort is ongoing. Each of the three dosing cohorts and the placebo control arm has 6 patients. Patients are treated for 28 days.